Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 5/20 | 0.48 |
| ▸ | PRKCQ | Q04759 | 7/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1330877 | 0.86 | MAPT (0.49) | PRKCQMETNPC1KDRHDAC6 | |
| SCHEMBL16012092 | 0.81 | PIN1 (0.64) | PIN1NPC1 | |
| SCHEMBL1265338 | 0.81 | PIN1 (0.53) | PIN1PRKCQ | |
| SCHEMBL3395746 | 0.81 | MET (0.48) | METNPC1KDRHDAC6 | |
| SCHEMBL3971786 | 0.80 | PIN1 (0.65) | PIN1PRKCQ | |
| SCHEMBL3854087 | 0.79 | PRKCQ (0.54) | PIN1PRKCQ | |
| SCHEMBL2598659 | 0.78 | PIN1 (0.46) | PIN1PRKCQ | |
| SCHEMBL1917607 | 0.77 | PIN1 (0.57) | PIN1PRKCQ | |
| SCHEMBL2177207 | 0.77 | MAPT (0.42) | METNPC1KDRHDAC6 | |
| SCHEMBL27845606 | 0.76 | PDE5A (0.56) | PIN1PRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247185-B1 | TYROSINE KINASE INHIBITORS | TIGER PHARMATECH (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-2247185-B1 | TYROSINE KINASE INHIBITORS | TIGER PHARMATECH (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8598184-B2 | Protein kinase inhibitors | TIGER PHARMATECH (US) | 2013-12-03 | — | — | US | disclosed |
| CN-102014631-A | Tyrosine kinase inhibitors | TIGER PHARMATECH | 2011-04-13 | — | — | CN | disclosed |
| US-20100324074-A1 | Protein Kinase Inhibitors | ZHANG JUNHU | 2010-12-23 | — | — | US | disclosed |
| US-20100324074-A1 | Protein Kinase Inhibitors | ZHANG JUNHU | 2010-12-23 | — | — | US | disclosed |
| US-20100324074-A1 | Protein Kinase Inhibitors | ZHANG JUNHU | 2010-12-23 | — | — | US | disclosed |
| EP-2247185-A2 | TYROSINE KINASE INHIBITORS | Tiger Pharmatech (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009111354-A2 | TYROSINE KINASE INHIBITORS | TIGER PHARMATECH (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324074-A1 | Protein Kinase Inhibitors | MET, ABL1, ERBB2 | PIN1 1760/4885PRKCQ 151/4885MET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.